Phase I Study of Milatuzumab for Graft Versus Host Disease
Status:
Terminated
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and tolerability of milatuzumab (IMMU-115) when added to a
standard regimen to prevent Graft vs. Host Disease (GVHD) in patients with hematologic
malignancies undergoing stem cell transplant.